Literature DB >> 19555417

Quantitation of human herpesvirus 8 (HHV-8) antibody in patients transfused with HHV-8-seropositive blood.

Ashley L Fowlkes1, Cedric Brown, Minal M Amin, John D Roback, Robert Downing, Esau Nzaro, Jonathan Mermin, Wolfgang Hladik, Sheila C Dollard.   

Abstract

BACKGROUND: Human herpesvirus 8 (HHV-8) is endemic in Uganda where seroprevalence is approximately 40%. In a previous study, Ugandan patients receiving blood transfusions had multiple serum specimens collected for 6 months after transfusion to monitor for HHV-8 infection. It was observed that several HHV-8-seronegative patients were unexpectedly HHV-8 seropositive after blood transfusion. STUDY DESIGN AND METHODS: This study measured HHV-8 antibody in serially collected serum specimens from 542 patients who received transfusions and evaluated the risk of HHV-8 infection as a function of HHV-8 antibody levels in the donors.
RESULTS: HHV-8 antibody was observed in 52% of patients transfused with HHV-8-seropositive blood in amounts that corresponded with their donor's antibody titer and waned within 40 days. Higher levels of passive HHV-8 antibody in patients who received transfusions appeared to be associated with a lower risk of HHV-8 infection.
CONCLUSION: The source of transient antibody in patients who received transfusions was determined to be the transfused blood. Donors with higher HHV-8 antibody titers may have been less likely to have infectious virus in the blood.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19555417     DOI: 10.1111/j.1537-2995.2009.02269.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  2 in total

Review 1.  Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma.

Authors:  Thomas S Uldrick; Denise Whitby
Journal:  Cancer Lett       Date:  2011-03-04       Impact factor: 8.679

2.  Prevalence of human herpesvirus 8 and hepatitis C virus in a rural community with a high risk for blood-borne infections in central China.

Authors:  T Zhang; N He; Y Ding; K Crabtree; V Minhas; C Wood
Journal:  Clin Microbiol Infect       Date:  2011-03       Impact factor: 8.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.